FinCanna Capital Corp. Closes $2,680,960 First Tranche of Private Placement
FinCanna Capital Corp. Closes $2,680,960 First Tranche of Private Placement
Not for distribution to United States newswire services or for dissemination in the United States.
VANCOUVER, British Columbia, April 05, 2018 -- FinCanna Capital Corp. (“ FinCanna”) (CSE:CALI) (OTCQB:FNNZF)
announced that it has closed the first tranche of the private placement announced on February 21, 2018. The Company issued
3,829,944 Units at a price of $0.70 per unit for gross proceeds of $2,680,960. The Company expects a second tranche of the
Private Placement to close on a final amount within the following week.
Each Unit consisted of one common share of FinCanna and one-half of one common share purchase warrant. Each full warrant
will be exercisable to acquire one common share of FinCanna at an exercise price of C$1.05 for 24 months from closing. The
common share purchase warrants will be subject to acceleration at FinCanna’s discretion in the event its common shares
trade on the Canadian Securities Exchange on a volume weighted average price (“VWAP”) basis of C$1.40 or more for a period
of ten consecutive trading days.
All securities issued will be subject to a four-month hold period expiring on August 6, 2018.
FinCanna intends to use the net proceeds from the Private Placement to fund additional royalty investment opportunities and
the Company’s ongoing working capital and general corporate purposes.
FinCanna has paid a finder’s fee of 8% on a portion of the proceeds raised from subscriptions arranged by certain finders in
cash and / or warrants equal to 8% of the aggregate Units subscribed for pursuant to the subscriptions arranged by such
finders. Each warrant shall be exercisable for one common share at a price of C$1.05 for a period of 24 months from closing.
The lead finder in the non-brokered private placement is Triview Capital Ltd.
This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the
United States. The securities have not been and will not be registered under the United States Securities Act of 1933,
as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to
U.S. Persons unless registered under the 1933 Act and applicable state securities laws or an exemption from such
registration is available
About FinCanna Capital Corp.
FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on
revenues. FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in
scalable, best-in-class projects and companies in U.S. legal states, with a focus on California. For additional information visit
www.fincannacapital.com and FinCanna’s profile at www.sedar.com.
FinCanna Capital Corp.
Andriyko Herchak, CEO & Director
Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking information based on current expectations. Statements about, among other
things, the closing of the Private Placement, expected terms and conditions of the Private Placement, the completion, terms
and size of the Private Placement and the use of proceeds of the Private Placement are all forward-looking information. These
statements should not be read as guarantees of future performance or results. Such statements involve known and unknown
risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different
from those implied by such statements. Such factors include, but are not limited to: the ability to find suitable subscribers for
the Private Placement. Although such statements are based on management’s reasonable assumptions at the date such
statements are made, there can be no assurance that the Private Placement will occur or that, if the Private Placement does
occur, it will be completed on the terms described above and that such forward-looking information will prove to be accurate,
as actual results and future events could differ materially from those anticipated in such forward-looking information.
Accordingly, readers should not place undue reliance on the forward-looking information. FinCanna assumes no responsibility
to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.